Next Phase Newsletter

A newly established venture capital firm headquartered in Western Europe is tied with a dedicated life sciences consulting firm with multiple offices throughout USA, Europe, and Asia. With the capability to leverage the experienced resources from the consulting firm, the firm is able to invest in and support in early-stage technologies with a derisked strategy. The firm has a pan-European focus and is sourcing globally within industry, start-up communities, and business accelerators, for high potential opportunities.

The firm is interested in proprietary, differentiated therapeutic products addressing high-unmet medical need and platform technologies supporting next-generation patient diagnosis, treatment and disease prevention. The interest areas also include genomics, AI, diagnostics, medical devices, rare diseases, next generation personalized medicine, and more. The firm is interested in early-stage opportunities – pre-clinical assets with a valid proof of concept, devices with a working prototype are all good fits in terms of stage of development.

The firm will look at each opportunity carefully, and is most interested in those with business potential with a 3-5 year runway to strategic partnerships, acquisition by large life science companies or an IPO. The firm will prefer to lead investments and will take a very active role in their portfolio companies, often being involved in the operations of these companies to support their growth and enabling research that generates important, proof-of-concept data.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm based in the US looks to invest in healthcare companies of strategic interest to a major healthcare insurance company that the firm has ties with, while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe that are commercializing in the US or plan to in the near future. The firm also manages other funds that seek to invest in food and agriculture companies and insurtech companies, respectively.

Within the healthcare space, the firm looks to invest across Healthcare IT, Services, Diagnostics, and Devices, and agnostic towards types of technologies and indication areas the technologies address.

The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and prefers to lead in rounds but can co-invest in certain circumstances. The firm generally looks to take a board seat following an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech company based in the USA has an active pipeline of therapeutic assets in immuno-oncology and autoimmune diseases. The firm has been seeking novel therapeutics opportunities that are synergistic with the firm’s existing pipeline for potential licensing, investment, and other partnership opportunities. The firm is most interested in opportunities based in US and Europe.

The firm is seeking therapeutic opportunities for potential licensing, investment, and other win-win partnership opportunities. The firm is open to novel targets and modalities; in terms of indication/disease area, the firm is only considering immuno-oncology and autoimmune diseases at this time. In terms of stage of development, the firm will primarily consider pre-clinical stage assets.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly formed corporate VC of a pharmaceutical company is investing from an evergreen fund. The firm is interested in investing in companies in therapeutics, AI/ML drug discovery tools, digital therapeutics, virtual care platforms and connected devices. For therapeutics companies, the firm prefers to invest in companies that are preclinical, before IND. For other companies, the firm prefers to invest close to revenue, post pilot. The firm invests in companies based in North America, Europe and Israel from pre-seed to Series A, and will invest between .5-4M EUR in their first round, with capital reserved for follow on investments.

Historically, the firm has focused on CNS disorders and rare diseases, including areas such as neurodevelopment, epilepsy and mental health. The firm is investing in this area, with an additional focus on pregnancy, childbirth and women’s health.

The firm takes at minimum a board observer seat when investing, and look to help the company strategically with their expertise and network.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital/private equity firm based in the US invests in both digital health technologies and the life sciences. For their life sciences investments, most of them are in therapeutics, with about 5% of their investments going to life science tools and diagnostics. For therapeutics companies, the firm prefers to see efficacy and safety data before investing. For tools, diagnostics and digital health companies, the companies should be either revenue generating, or, at minimum, revenue in sight. The firm will consider global opportunities, but invests primarily in the US, and generally invests 5-15M in their early stage deals.

For therapeutics companies, the firm is modality and indication agnostic, although is less interested in microbiotic-related therapeutics. The firm prefers platform technologies, or an associative program; they do not invest in single assets. For digital health companies, the firm invests primarily in enterprise software, such as clinical data management, tools to enable better care and healthcare IT companies.

The firm generally leads or co-leads investments, and will take a board seat after investing. For therapeutics companies, the firm prefers the startups to have raised 1-5M in a previous round before investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm focuses its investments on data moat and network effect. The firm currently manages over $1B AUM and since inception, has invested in over 260 companies from seed to growth stages and continues to seek investment opportunities across the globe.

Within life sciences and healthcare, the firm invests in digital health and technologies that leverage AI, big data, and other applications in the intersection of science and technology. While the firm does not typically invest in traditional therapeutics, but has invested in medical device and diagnostic companies in the past. In terms of stage of development, the firm is open to the earliest stages of development and is agnostic towards indication area.

The firm seeks to work with dedicated, experienced management teams. The firm is open to working with first time entrepreneurs, and often acts as the first institutional investor. The firm is open to either acting as a lead or co-investor, and seeks board representation when leading.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical company headquartered in Asia has 40 branches and subsidiaries around the world (including the United States, Japan, Germany, Russia, Spain, India, etc.). The firm’s main business covers chemical and biological medicines, pharmaceutical packaging, and trading.

The firm’s investment subsidiary is responsible for equity investment and in-licensing activities for its corporate parent.

The firm is most interested in companies developing novel drugs in Biologics, Cell therapy, Gene therapy, Repurposed drugs, and Biosimilars. The firm is interested in distribution rights in China. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.